Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 09101 | First Coast Service Options, Inc. | A and B MAC | FL |
| 09201 | First Coast Service Options, Inc. | A and B MAC | PR VI |
| 09102 | First Coast Service Options, Inc. | A and B MAC | FL |
| 09202 | First Coast Service Options, Inc. | A and B MAC | PR |
| 09302 | First Coast Service Options, Inc. | A and B MAC | VI |
Billing and coding: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57063 (Billing and Coding: Diagnostic and Therapeutic Esophagogastroduodenoscopy) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown.
A57063: Billing and Coding: Diagnostic and Therapeutic Esophagogastroduodenoscopy (Billing and Coding, effective 2025-10-01)
- Covered ICD-10-CM codes
- 820
- 1 group
- Non-covered ICD-10-CM codes
- 1
- Procedure codes listed
- 21
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| B25.2 | — |
| B37.81 | — |
| C15.3 | — |
| C15.4 | — |
| C15.5 | — |
| C15.8 | — |
| C15.9 | — |
| C16.0 | — |
| C16.1 | — |
| C16.2 | — |
| C16.3 | — |
| C16.4 | — |
| C16.5 | — |
| C16.6 | — |
| C16.8 | — |
| C16.9 | — |
| C17.0 | — |
| C17.1 | — |
| C17.2 | — |
| C17.3 | — |
| C17.8 | — |
| C17.9 | — |
| C22.0 | — |
| C22.2 | — |
Procedure codes: 43233, 43235, 43236, 43237, 43238, 43239, 43241, 43243, 43244, 43245, 43246, 43247, 43248, 43249, 43250, 43251, 43253, 43254, 43255, 43266, 43270.
Coverage indications, limitations and medical necessity
History/Background and/or General Information
Upper intestinal endoscopy is performed with a lighted, flexible, fiberoptic instrument passed through the cricopharynx. The patient receives conscious sedation. A topical anesthetic is sometimes applied to the posterior pharynx. Direct visualization of the entire esophagus, stomach, and duodenum (to the junction of the second and third portions) can be accomplished easily with modern instruments that are less than 12mm in diameter. Esophagogastroduodenoscopy (EGD) is a technique utilized to examine, obtain samples, and in some instances, to treat pathological conditions.
Diagnostic observations are made concerning focal benign or malignant lesions, diffuse mucosal changes, luminal obstruction, motility, and extrinsic compression by contiguous structures. A diagnostic EGD allows the examiner to visualize abnormalities detectable by the technique and to photograph, biopsy, and/or remove lesions as appropriate.
The purpose of the therapeutic EGD is to manage hemorrhage; remove foreign bodies and neoplastic growths; to relieve obstruction due to stricture, malignancy, or other causes through dilatation or the placement of stents; and to assist in the placement of percutaneous gastrostomy tubes.
Covered Indications
EGD(s)will be considered medically reasonable and necessary under the following diagnostic conditions:
• Patient has upper abdominal distress (e.g., gastroesophageal reflux disease) which persists despite an appropriate trial of symptomatic therapy;
• Patient has upper abdominal distress associated with a short history of signs and symptoms suggesting significant associated disease or illness (e.g., weight loss, anorexia, vomiting, nonsteroidal anti-inflammatory drug [NSAID] intake, other gastric irritant intake);
• Patients over the age of 40 who have experienced a significant history of heartburn that returns after a course of symptomatic therapy;
• Patients who have dysphagia or odynophagia;
• Patient has persistent, unexplained vomiting;
• Patient has upper gastrointestinal x-ray findings of:
• any lesion that requires biopsy for diagnosis; or
• gastric ulcer suspicious of cancer; or
• evidence of stricture or obstruction;
• To assess acute injury after caustic agent ingestion;
• When anti-reflux surgery is contemplated; or
• Patient has gastrointestinal bleeding:
• in most actively bleeding patients; or
• for presumed chronic blood loss and iron deficiency anemia when investigation of large bowel is negative.
EGD(s) will be considered medically reasonable and necessary for the following therapeutic purposes:
• Treatment of bleeding lesions;
• Removal of foreign bodies;
• Sclerotherapy and/or band ligation for bleeding from esophageal or gastric varices;
• Dilatation of strictures in the upper intestinal tract;
• Removal of selected polypoid lesions;
• Placement of feeding tubes; or
• Palliative therapy of stenosing neoplasms (e.g., laser, stent placement).
Gastrointestinal bleeding may be treated with a variety of methods. Direct contact heater probes and hemostatic injections into or around the bleeding vessels are both effective therapy for acute bleeding.
Foreign body removal from the stomach or esophagus is usually successful with these flexible instruments. The foreign bodies can be retrieved by either of two methods. The first method is to capture the foreign body with a snare device/grasping forceps and pull the item out with the endoscope. The second method is accomplished by piecemeal destruction and pushing the bolus through the esophagus into the stomach.
Esophageal varices may be injected with a variety of sclerosing solutions. Eradication of varices requires, on the average, five sclerotherapy sessions, with multiple injections given during each session.
Dilatation of strictures may be accomplished with a balloon placed through the endoscope and inflated using hydrostatic pressure. Bougies are rubber dilators available in various sizes up to approximately 2.0cm. Plastic bougies and other dilating probes are usually passed over a guide wire. This procedure involves placing the guide wire into the stomach through the endoscope. The endoscope is then withdrawn leaving the guide wire in place. The dilating probes and plastic bougies are then passed over the guide wire. After the largest dilator is used, the dilator and guide wire are removed. Esophageal dilation is performed after a definitive diagnosis has been established in patients exhibiting dysphagia. The goal in most cases is a lumenal diameter of 16-17mm which allows passage of solid food. A series of dilators may be passed over the guide wire to reach the goal of therapy.
Follow-up EGD(s)will be considered medically reasonable and necessary for the following indications:
• Biopsy surveillance of patients with Barrett’s esophagus every 12 to 24 months. However, if dysplasia is present, earlier surveillance intervals of from three to six months may be required;
• Follow-up of gastric ulcers to healing or satisfaction that they are benign;
• Follow-up and treatment of esophageal strictures requiring guidewire dilation;
• Follow-up of duodenal ulcer or other lesions of the upper gastrointestinal tract that have resulted in serious consequences (e.g., hemorrhage);
• Follow-up of patients having a previous gastric polypectomy for adenoma; or
• Follow-up and treatment of patients with esophageal varices or bleeding lesions requiring recurrent therapy (e.g., esophageal varices, gastric varices, angiodysplastic or watermelon stomach lesions, radiation gastritis).
• Follow-up for removal of percutaneous gastrostomy tube (PEG)
Limitations
Periodic EGD is NOT usually indicated in the following situations:
• Surveillance of healed, benign disease such as gastric or duodenal ulcer or benign esophageal strictures; or
• Cancer surveillance in patients with pernicious anemia, treated achalasia, or prior gastric resection.
EGD is generally contraindicated for patients with recent myocardial infarction.
As published in the CMS IOM Publication 100-08, Medicare Program Integrity Manual , Chapter 13, Section 13.5.4, an item or service may be covered by a contractor LCD if it is reasonable and necessary under the Social Security Act Section 1862 (a)(1)(A). Contractors shall determine and describe the circumstances under which the item or service is considered reasonable and necessary.
Summary of evidence (opening)
N/A
The contractor cites 2 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2015-10-01
- Current revision effective
- 2019-10-01
- Last reviewed by the contractor
- 2018-08-08
- MCD version
- 21
- Derived from
- L28823
The contractor lists 2 National Coverage Determinations as related: NCD 100.2 Endoscopy, NCD 100.3 24-Hour Ambulatory Esophageal pH Monitoring. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line, and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the First Coast Service Options, Inc. hub lists every other active policy from the same contractor.
Frequently asked questions
What does LCD L33583 cover?
Upper intestinal endoscopy is performed with a lighted, flexible, fiberoptic instrument passed through the cricopharynx. The patient receives conscious sedation. A topical anesthetic is sometimes applied to the posterior pharynx. Direct visualization of the entire esophagus, stomach, and duodenum (to the junction of the second and third portions) can be accomplished easily with modern instruments that are less than… The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database export of September 24, 2026.
Which states does LCD L33583 apply to?
First Coast Service Options, Inc. applies it to Medicare claims in FL, PR, VI. A Local Coverage Determination binds only the contractor that wrote it; the same service in another jurisdiction is judged under that contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L33583?
The companion billing and coding article A57063 lists 820 ICD-10-CM codes in 1 group that support medical necessity and 1 that do not; the first 24 appear on this page and the complete list is in the article on cms.gov.
How do I appeal a denial under LCD L33583?
The remittance carries claim adjustment reason code 50 with remark code N115, naming the LCD. Compare the documented indication with the policy's covered indications and the article's diagnosis list, then file a redetermination within 120 days with the record attached; if the service genuinely falls outside the policy, the patient can be billed only when a valid Advance Beneficiary Notice was obtained before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-09-24 · effective 2026-09-20 · file lcd.csvSHA-256 2fcc4251b6ddd1eb…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-09-24 · effective 2026-09-20 · file article.csvSHA-256 f31932f1df3b4035…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.